|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT03719469 |
|
Date of registration:
|
06/09/2018 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Circulating microRNAs as Novel Prognosis Biomarkers for Rheumatoid Arthritis
|
|
Scientific title:
|
Circulating microRNAs Expression as Predictors of Clinical Response in Rheumatoid Arthritis Patients Treated With Green Tea |
|
Date of first enrolment:
|
January 20, 2015 |
|
Target sample size:
|
150 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT03719469 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- subjects (aged 18-65 years) who were diagnosed as RA with moderate to severe activity
at the division of rheumatology and clinical immunology at Mansoura University,
between 20 January/2015 and 20 September 2015 were recruited in this prospective
study.
- According to the diagnostic criteria of the American College of Rheumatology (Arnett
et al., 1988), all patients classified as showing established RA for more than 8
years.
- Only patients who had higher scores of DAS28-ESR, RA biomarkers, and established
radiographic analysis, and were diagnosed with RA according to the 2010ACR/ EULAR
classification criteria were included in this study.
Exclusion Criteria:
• Patients who received non-steroidal anti-inflammatory drugs, oral glucocorticoids, had a
history of severe deformation of joint, pregnant or lactating women were excluded from this
study.
Age minimum:
18 Years
Age maximum:
85 Years
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Rh Disease
|
|
Intervention(s)
|
|
Dietary Supplement: Green tea group
|
|
Primary Outcome(s)
|
|
Functional status
[Time Frame: change from baseline functional status at 24 weeks]
|
|
Secondary Outcome(s)
|
|
Pain intensity
[Time Frame: change from baseline functional status at 24 weeks]
|
|
Abnormal cell physiology and the parthenogenesis of Rheumatoid arthritis (RA)
[Time Frame: change from baseline functional status at 24 weeks]
|
|
Secondary ID(s)
|
|
RRC-2015-058
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|